Johnson & Johnson Marks 100,000 US Implants of Tecnis Odyssey IOL; Showcases Innovations at AAO 2025
Johnson & Johnson announced that its Tecnis Odyssey IOL has now been implanted in 100,000 eyes since its 2024 launch.
The company will highlight this milestone alongside new data presentations and technology showcases at the upcoming American Academy of Ophthalmology (AAO) annual meeting, taking place October 18-20, 2025. Johnson & Johnson will present the Tecnis Odyssey IOL, advances in laser cataract surgery and phacoemulsification technologies, and results from investigator-initiated studies validating surgical outcomes and patient satisfaction across its cataract and refractive surgery portfolio.
The Tecnis Odyssey IOL achieves over 95% light utilization,¹ supporting exceptional image quality,²⁻⁴ and visual acuity for patients seeking sharp, clear vision in real-world conditions.⁵⁻⁶ In clinical comparisons, the Odyssey lens demonstrated superior contrast sensitivity day and night, outperforming a leading monofocal competitor under low-light conditions.²⁻³⁻⁷
Additional benefits include:
Enhanced tolerance to refractive error⁸
Optimized dysphotopsia profile⁹
Superior range of vision¹⁰
Johnson & Johnson will also showcase updates across its surgical equipment platforms, including the Catalys Precision Laser System and the Veritas Vision System.
The Catalys System, which achieved the #1 utilization rate among laser cataract surgery systems in 2023,¹¹ now features the cOS 7.0 software upgrade. The new version integrates with biometers for streamlined preoperative measurement and astigmatism management. Early users reported 100% confidence in treating a broader range of patients with enhanced precision, and the upgrade is now available in the U.S.¹²
The Veritas Vision System continues to elevate phacoemulsification performance with Hybrid Fluidics Technology, combining an Advanced Tubing System (ATS), Dual Pump, and Advanced Infusion for exceptional anterior chamber stability and surgeon control¹³⁻¹⁷. At AAO, attendees will experience the system’s advanced features firsthand through interactive wet lab demonstrations.
Clinical Data: Reinforcing Confidence in Patient-Centered Outcomes
New investigator-initiated studies underscore the safety, performance, and patient satisfaction achieved across Johnson & Johnson’s IOL portfolio.
Optical Phenomena and Tolerance to Simulated Astigmatism of a Violet-Light Filtering Diffractive Full-Range Vision IOL
Karolinne Rocha, MD, et al. (ClinicalTrials.gov ID: 30082042)
This study evaluated visual outcomes with the TECNIS ODYSSEY IOL, demonstrating satisfactory tolerance to induced astigmatism and favorable optical performance under simulated conditions.Clinical and Patient-Reported Outcomes of Mild Glaucoma Patients Implanted with Extended Depth of Focus IOLs
Zarmeena Vendal, MD (ClinicalTrials.gov ID: 30083549)
Patients bilaterally implanted with TECNIS Symfony™ OptiBlue™ IOLs achieved 20/30 or better vision at all distances, with spectacle independence for both distance and intermediate vision—suggesting that violet-light filtering EDOF IOLs may offer glaucoma patients excellent vision quality across the visual spectrum.
Attendees can explore Johnson & Johnson’s latest innovations and clinical insights at booth #2509 during the 2025 AAO Annual Meeting.
References
- Weeber, Henk et al. Light Utilization of Diffractive Intraocular Lenses. Association for Research in Vision and Ophthalmology 2025. May 8 2025.
- Data on File. DOF2023CT4007
- Data on File. DOF2019OTH4002
- Data on File. 2024DOF4033
- Data on File. DOF2023CT4023
- Data on File. DOF2023CT4050
- Data on File. 2024DOF4033
- Data on File. 2024DOF4003
- Data on File. 2024DOF4005
- DOF2023CT4023 Data on File. DOF2020CT4014 - Forte 1: A Comparative Clinical Evaluation of a New TECNISTM Presbyopia Correcting Intraocular Lens Against a PanOptix® Intraocular Lens - DEFOCUS CURVES AND VISUAL ACUITY RESULTS.
- Data on file, 2021- 2023 US Market, 2024DOF4021
- Johnson & Johnson, 2023. Data on file. LMR Survey - Phase II Results. DOF2023CT4047.
- DOF2021MLT4002 Post-occlusion Surge Comparison Study
- DOF2021OTH4005 VERITAS Vision System Features
- DOF2021OTH4006 R&D Memo - Design intent for VERITAS Vision System
- Z370584 VERITAS Operator Manual Rev E. page 3-4, 3-5, 3-6
- Z370584 VERITAS Operator Manual Rev E. page 1-6, 1-8, 1-9, 3-7